PRP, prolotherapy, and where peptides sit in regenerative care
Regenerative care spans very different treatments — here is what separates PRP, prolotherapy, and peptides.
TL;DR
- PRP, prolotherapy, and peptides are different substances with different rules and evidence.
- PRP uses a person's own blood; prolotherapy uses an irritant solution; peptides are lab-made molecules.
- Peptides have the thinnest human evidence and least settled regulatory status of the three.
What regenerative care means
Regenerative care (in plain English: treatments meant to help tissue repair itself) is an umbrella term, not one product. Under it sit three approaches: PRP, or platelet-rich plasma (a concentrate from a person's own blood); prolotherapy (an irritant solution injected to trigger healing); and injectable peptides (short chains of amino acids that signal cells). Each differs in material, regulation, and evidence.
How PRP, prolotherapy, and peptides work
Picture a toolbox with three different tools, not one gadget. PRP is spun from a patient's own blood in a centrifuge (in plain English: a machine that separates blood into layers), then re-injected near the injury. Prolotherapy injects an irritant, often dextrose (sugar), to provoke inflammation that may kickstart repair. Peptides bind receptors (in plain English: docking sites on a cell) and trigger a signal — a key turning a lock, not a repair job.
Who asks about it
People come to this topic when an injury has not responded to rest, physical therapy, or standard injections, and they are weighing options before surgery. Others meet peptides while researching PRP and want to know how the three relate, since clinics now bundle them under one "regenerative" label.
What the research says
The evidence is mixed and inconsistent (in plain English: heterogeneous). A Cochrane review found three randomized trials covering 206 participants showed prolotherapy alone was no more effective than a control injection for chronic low-back pain (Cochrane, 2007). A 2020 meta-analysis of 34 randomized trials and over 2,800 knees found PRP outperformed placebo and hyaluronic acid at 6 to 12 months (PubMed, 2020). Peptide research is earlier-stage — mostly cells or animals, with far fewer human trials.
What to know before considering it
Regulatory status differs sharply. The FDA (Food and Drug Administration) does not regulate PRP as a human cell or tissue product, or HCT/P, since it classifies PRP as a blood product (FDA, 2017). Prolotherapy uses FDA-approved ingredients like dextrose. Peptides sit in the least settled place: some are FDA-approved drugs, others only exist through compounding pharmacies. Any peptide access requires evaluation by a licensed clinician.
The Halftime POV
At Halftime Health, "regenerative care" is a useful category and a confusing one. PRP, prolotherapy, and peptides are not interchangeable, and none is settled science. We stay precise about each option and route peptide questions to a licensed clinician.
Related reading:
- What is a peptide?
- How peptides differ from supplements
- Soft tissue healing timelines
- Native, synthetic, and compounded
FAQ
Q: What is PRP in regenerative medicine? A: PRP stands for platelet-rich plasma. It is a concentrate made by drawing a small amount of a person's own blood, spinning it in a centrifuge to concentrate the platelets, and injecting that concentrate near an injury. The FDA treats PRP as a blood product, not a regulated tissue therapy.
Q: How is prolotherapy different from PRP? A: Prolotherapy injects an irritant solution, often a dextrose (sugar) solution, directly into ligaments or tendons to provoke local inflammation. PRP injects a concentrate of a patient's own platelets instead. The two use different materials and rest on different proposed mechanisms.
Q: Are peptides FDA-approved for regenerative use? A: Some peptides are FDA-approved drugs for specific, narrow indications. Many others used in regenerative care are only available through compounding pharmacies under evolving federal rules, not as approved treatments for tissue repair. Access should always go through a licensed clinician.
Q: Is PRP regulated by the FDA? A: The FDA does not regulate PRP under its human cells, tissues, and cellular and tissue-based products (HCT/P) framework, because it classifies PRP as a blood product rather than a tissue product. The devices used to prepare PRP remain subject to FDA oversight.
Q: What does the research say about regenerative care options? A: The evidence is mixed and varies widely by treatment and condition. Human trial data exists for both PRP and prolotherapy, with inconsistent results depending on preparation and dosing. Peptide research in this space is earlier-stage, with fewer controlled human trials.
Disclaimer
This article is educational and is not medical advice. Compounded medications are not FDA-approved. Clinical outcomes depend on individual factors and require physician evaluation. Results vary. Halftime Health is launching soon — join the waitlist to get updates.
Get updates
Halftime Health is launching soon. We'll share what we learn along the way — the research, the regulations, the real-world trade-offs. Join the waitlist and we'll email you when we're live.
Sources
- FDA — Same Surgical Procedure Exception under 21 CFR 1271.15(b), Guidance for Industry (2017)
- Cochrane — Dagenais S, Yelland MJ, Del Mar C, Schoene ML. Prolotherapy injections for chronic low-back pain (2007)
- PubMed — PRP Injections for the Treatment of Knee Osteoarthritis: A Meta-Analysis of Randomized Controlled Trials (2020)
Frequently asked questions
what is PRP in regenerative medicine
PRP stands for platelet-rich plasma. It is a concentrate made by drawing a small amount of a person's own blood, spinning it in a centrifuge to concentrate the platelets, and injecting that concentrate near an injury. The FDA treats PRP as a blood product, not a regulated tissue therapy.
how is prolotherapy different from PRP
Prolotherapy injects an irritant solution, often a dextrose (sugar) solution, directly into ligaments or tendons to provoke local inflammation. PRP injects a concentrate of a patient's own platelets instead. The two use different materials and rest on different proposed mechanisms.
are peptides FDA-approved for regenerative use
Some peptides are FDA-approved drugs for specific, narrow indications. Many others used in regenerative care are only available through compounding pharmacies under evolving federal rules, not as approved treatments for tissue repair. Access should always go through a licensed clinician.
is PRP regulated by the FDA
The FDA does not regulate PRP under its human cells, tissues, and cellular and tissue-based products (HCT/P) framework, because it classifies PRP as a blood product rather than a tissue product. The devices used to prepare PRP remain subject to FDA oversight.
what does the research say about regenerative care options
The evidence is mixed and varies widely by treatment and condition. Human trial data exists for both PRP and prolotherapy, with inconsistent results depending on preparation and dosing. Peptide research in this space is earlier-stage, with fewer controlled human trials.
Keep reading
A licensed physician can build a protocol from your own labs.
Membership from $69/mo, including your onboarding panel. Each protocol is its own monthly subscription.